Research Analysts’ Recent Ratings Changes for IQVIA (IQV)

A number of firms have modified their ratings and price targets on shares of IQVIA (NYSE: IQV) recently:

• 10/14/2026 – IQVIA had its price target raised by Stifel Nicolaus from $276.00 to $303.00. They now have a “buy” rating on the stock.
• 10/7/2026 – IQVIA had its price target raised by Mizuho from $275.00 to $300.00. They now have an “outperform” rating on the stock.
• 10/7/2026 – IQVIA had its price target raised by Barclays PLC from $275.00 to $300.00. They now have an “overweight” rating on the stock.
• 9/30/2026 – IQVIA is now covered by UBS Group AG. They set a “buy” rating and a $345.00 price target on the stock.
• 9/30/2026 – IQVIA was upgraded by UBS Group AG to “strong-buy”.
• 9/29/2026 – IQVIA had its price target raised by Royal Bank Of Canada from $247.00 to $319.00. They now have an “outperform” rating on the stock.
• 9/28/2026 – IQVIA had its “buy” rating reaffirmed by Truist Financial Corporation. They now have a $329.00 price target on the stock, up from $300.00.
• 9/24/2026 – IQVIA was upgraded by Weiss Ratings from “hold (c)” to “hold (c+)”.
• 9/17/2026 – IQVIA had its price target raised by Morgan Stanley from $240.00 to $270.00. They now have an “equal weight” rating on the stock.
• 9/12/2026 – IQVIA was upgraded by Wall Street Zen from “hold” to “buy”.
• 8/29/2026 – IQVIA was downgraded by Wall Street Zen from “buy” to “hold”.

Insider Activity at IQVIA

In other IQVIA news, insider Keriann Cherofsky sold 558 shares of the business’s stock in a transaction on Wednesday, July 29th. The stock was sold at an average price of $245.21, for a total value of $136,827.18. Following the transaction, the insider owned 2,989 shares of the company’s stock, valued at approximately $732,932.69. The trade was a 15.73% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider W. Richard Staub sold 5,500 shares of the business’s stock in a transaction on Monday, August 3rd. The stock was sold at an average price of $232.68, for a total value of $1,279,740.00. Following the completion of the transaction, the insider directly owned 13,312 shares in the company, valued at approximately $3,097,436.16. This represents a 29.24% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 15,581 shares of company stock valued at $3,796,021 in the last ninety days. Insiders own 1.70% of the company’s stock.

IQVIA Holdings Inc is a global provider of technology, analytics and contract research services for the life sciences industry. The company helps pharmaceutical, biotechnology and medical device organizations develop, commercialize and improve products by combining healthcare data with advanced analytics, consulting and technology-enabled services.

Its offerings include clinical research and trial management, real-world evidence, healthcare data and analytics, regulatory and safety services, technology platforms, and commercial solutions.